NITROGEN-CONTAINING HETEROCYCLIC COMPOUND SALT OR CRYSTAL THEREOF, PHARMACEUTICAL COMPOSITION, AND FLT3 INHIBITOR
申请人:Fujifilm Corporation
公开号:EP3059227A1
公开(公告)日:2016-08-24
An object of the present invention is to provide a compound and pharmaceutical composition showing superior stability and/or solubility, etc. and having superior FLT3 inhibitory activity. The present invention provides a salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)ammo)-4-(propylanmio)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide, or a crystal thereof. Since the salt or a crystal thereof has superior FLT3 inhibitory activity and shows superior physicochemical properties as drugs, such as storage stability, solubility, and so forth, it is useful for treatments of diseases or conditions relating to FLT3. The present invention also provides a pharmaceutical composition and FLT3 inhibitor containing the salt or a crystal thereof.
本发明的目的是提供一种化合物和药物组合物,该化合物和药物组合物显示出优异的稳定性和/或溶解性等,并具有优异的FLT3抑制活性。本发明提供了(S,E)-N-(1-((5-(2-((4-氰基苯基)氨基)-4-(丙基氨基)嘧啶-5-基)戊-4-炔-1-基)氨基)-1-氧代丙烷-2-基)-4-(二甲基氨基)-N-甲基丁-2-烯酰胺的盐或其晶体。由于该盐或其晶体具有优异的FLT3抑制活性,并显示出作为药物的优异理化性质,如储存稳定性、溶解性等,因此可用于治疗与FLT3有关的疾病或病症。本发明还提供了含有其盐或晶体的药物组合物和FLT3抑制剂。